Drug Trial Radar · NCT07217678
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
Last checked: Nov 20, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Feb 9, 2026
Primary completion
Jan 31, 2028
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- University of MiamiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AbbVie
- First posted
- Oct 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.
Conditions
- Glaucoma
- Open-Angle Glaucoma
- Ocular Hypertension
- Glaucoma Suspect
Interventions
Durysta, Bimatoprost Intracameral Implant 10 µgDrug
Participants in this arm will receive a one-time injection of Durysta (intracameral bimatoprost 10mcg). Participants will be followed by a total of 3 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Caspase-1 mRNA Expression Following Durysta InjectionTime frame: Baseline, post-injection 1 month, post-injection 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bascom Palmer Eye Institute
Miami, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.